Three deaths in Novartis CAR T-cell therapy trials for autoimmune disease prompt caution
Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.
